Abstract
In Japan, with advances in image-guided radiation therapy, many retrospective clinical trials have been made in order to examine the effect and safety of stereotactic body radiation therapy (SBRT) for early stage lung cancer. The results of these trials were quite promising. On the basis of these results, the Japan Clinical Oncology Group (JCOG) launched the new study group in it, which is the JCOG Radiation Therapy Study Group. This group has conducted two prospective clinical trials; one is the JCOG0403 and the other is the JCOG0702. The JCOG0403 showed that SBRT was a standard treatment for patients with stage IA lung cancer who could not be candidates for surgery, and that SBRT could be presented as an alternative for patients with the same stage who refused surgery. The JCOG0702 proved that the increase of the total dose could be safely with SBRT for patients of T2 lung cancer.
Keywords
Stereotactic body radiation therapy SBRT Japan Clinical Oncology Group JCOG0403 JCOG0702References
- 1.Uematsu M, Shioda A, Suda A, Fukui T, Ozeki Y, Hama Y, et al. Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience. Int J Radiat Oncol Biol Phys. 2001;51:666–70.PubMedCrossRefGoogle Scholar
- 2.Onimaru R, Shirato H, Shimizu S, Kitamura K, Xu B, Fukumoto S, et al. Tolerance of organs at risk in small-volume, hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers. Int J Radiat Oncol Biol Phys. 2003;56:126–35.PubMedCrossRefGoogle Scholar
- 3.Nagata Y, Takayama K, Matsuo Y, Norihisa Y, Mizowaki T, Sakamoto T, et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys. 2005;63:1427–31.PubMedCrossRefGoogle Scholar
- 4.Koto M, Takai Y, Ogawa Y, Matsushita H, Takeda K, Takahashi C, et al. A phase II study on stereotactic body radiotherapy for stage I non-small cell lung cancer. Radiother Oncol. 2007;85:429–34.PubMedCrossRefGoogle Scholar
- 5.Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol. 2007;2(7 Suppl 3):S94–100.PubMedCrossRefGoogle Scholar
- 6.Nagata Y, Hiraoka M, Mizowaki T, Narita Y, Matsuo Y, Norihisa Y, et al. Survey of stereotactic body radiation therapy in Japan by the Japan 3-D Conformal External Beam Radiotherapy Group. Int J Radiat Oncol Biol Phys. 2009;75:343–7.PubMedCrossRefGoogle Scholar
- 7.Nagata Y, Hiraoka M, Shibata T, Onishi H, Kokubo M, Karasawa K, et al. Stereotactic body radiation therapy for T1N0M0 non-small cell lung cancer: first report for inoperable population of a phase II trial by Japan Clinical Oncology Group (JCOG 0403). Int J Radiat Oncol Biol Phys. 2012;84:S46.CrossRefGoogle Scholar
- 8.Nagata Y, Hiraoka M, Shibata T, Onishi H, Kokubo M, Karasawa K, et al. A phase II trial of stereotactic body radiation therapy for operable T1N0M0 non-small cell lung cancer: Japan Clinical Oncology Group (JCOG0403). Int J Radiat Oncol Biol Phys. 2010;78:S27–8.CrossRefGoogle Scholar
- 9.Onimaru R, Fujino M, Yamazaki K, Onodera Y, Taguchi H, Katoh N, et al. Steep dose-response relationship for stage I non-small-cell lung cancer using hypofractionated high-dose irradiation by real-time tumor-tracking radiotherapy. Int J Radiat Oncol Biol Phys. 2008;70:374–81.PubMedCrossRefGoogle Scholar
- 10.Onimaru R, Shirato H, Shibata T, Hiraoka M, Ishikura S, Onishi H, et al. A phase 1 study of stereotactic body radiation therapy (SBRT) for peripheral T2N0M0 non-small cell lung cancer (NSCLC): Japan Clinical Oncology Group Study (JCOG0702). Int J Radiat Oncol Biol Phys. 2013;87:S10.CrossRefGoogle Scholar